Dr Robert Salamon, MD in Bedford, OH - Plastic Surgery

Dr Robert Salamon, MD is a Plastic Surgery physician based in Bedford, Ohio. Dr Robert Salamon is licensed to practice in Ohio (license number 35-043637) and his current practice location is 50 Blaine Ave, #2300p, Bedford, Ohio. He can be reached at his office (for appointments etc.) via phone at (440) 232-8719.

NPI number for Dr Robert Salamon is 1952357642 and his current mailing address is Po Box 74751, Cleveland, Ohio. He does not participate in medicare program and thus does not accept medicare assignments. His NPI Number is 1952357642.

Contact Information

	Dr Robert Salamon, MD
	50 Blaine Ave, #2300p, Bedford, OH 44146-2709
	(440) 232-8719
	(440) 735-5135

Physician's Profile

Full Name	Dr Robert Salamon
Gender	Male
Speciality	Plastic Surgery
Location	50 Blaine Ave, Bedford, Ohio
Accepts Medicare Assignments	Does not participate in Medicare Program. He may not accept medicare assignment.

NPI Data:

NPI Number: 1952357642
Provider Enumeration Date: 05/25/2006
Last Update Date: 06/16/2008

Medical Identifiers

Medical identifiers for Dr Robert Salamon such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1952357642	NPI	-	NPPES
0566623	Medicaid	OH

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
208200000X	Plastic Surgery	35-043637 (Ohio)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Dr Robert Salamon is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Dr Robert Salamon, MD Po Box 74751, Cleveland, OH 44194-0834 Ph: (440) 232-0061	Dr Robert Salamon, MD 50 Blaine Ave, #2300p, Bedford, OH 44146-2709 Ph: (440) 232-8719

News Archive

TRYTON-LM clinical study enrolls first two patients

Tryton Medical, Inc., the leading developer of stents designed to definitively treat bifurcation lesions, today announced the enrollment of the first two patients in TRYTON-LM, a prospective, single-arm study evaluating the feasibility of the Tryton stent in conjunction with Abbott's XIENCE PRIME Everolimus Eluting Coronary Stent System to treat stable patients with complex de novo bifurcation lesions involving the left main coronary artery.

New biomarker may help identify patients at risk for graft-versus-host disease after stem cell transplants

A recent report published in Science Translational Medicine by MUSC Hollings Cancer Center investigator Sophie Paczesny, M.D., Ph.D., sheds light on immune cell biomarkers that may reveal which patients are most at risk for graft-versus-host disease (GVHD), a life-threatening condition that can arise after hematopoietic stem cell transplantation (HSCT) for treatment of liquid cancers such as leukemia.

Decision Resources: NSCLC drug market to grow from $4 billion in 2009 to over $6.5 billion in 2019

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues finds that the non-small-cell lung cancer (NSCLC) drug market will increase from approximately $4 billion in 2009 to more than $6.5 billion in 2019 in the United States, France, Germany, Italy, Spain, United Kingdom and Japan.

Verapamil drug may reverse diabetes-related death of pancreatic beta cells

A common high-blood-pressure medication appears to reverse the diabetes-related death of pancreatic beta cells, according to a University of Alabama at Birmingham study published today in the journal Diabetes.

Dr Robert Salamon, MD - Plastic Surgery in Bedford, OH